Drug profile · INN
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence
STRIMVELIS
- Patents linked
- 0
- News articles
- 0
Quick answer
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence (STRIMVELIS) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence
Brand STRIMVELIS
ATC code L03
Frequently asked questions
What is autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence?
autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence (STRIMVELIS) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence?
STRIMVELIS is a marketed brand name for autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with retroviral vector that encodes for the human ada cdna sequence. Check FDA Drugs@FDA for the current US label holder and prescribing information.